Compare AbCellera Biologics Inc (ABCL) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs DigitalOcean Holdings Inc — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while DigitalOcean Holdings Inc trades at $139.24 (market cap $14.30B). The key difference: DigitalOcean Holdings Inc is far larger — about 6.1× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.
| ABCL | DOCN | |
|---|---|---|
Market Cap | $2.35B | $14.30B |
Sector | Health | Technology |
52-Week High | $8.12 | $181.29 |
52-Week Low | $2.78 | $25.74 |
Enterprise Value | $1.99B | $14.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
DigitalOcean (DOCN) trades at $137.12, up 5.37% today amid strong Q2 2026 preliminary results showing accelerated growth. The stock exhibits bearish technical signals but maintains robust fundamentals with consistent earnings beats, 58.49% gross margins, and 24.97% net income margins. Recent news highlights inclusion in the Russell 1000 Index and AI-driven cloud demand, with analyst consensus bullish at a $169.91 price target.
Outlook remains positive given AI-native cloud positioning and revenue growth, though high valuation ratios (P/E 57.62) and negative shareholder equity pose risks. Upside depends on execution of growth initiatives, while competition and debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
